| 序號 | 藥品通用名稱 | 英文名稱/商品名 | 規格 | 劑型 | 持證商 | 備注1 | 備注2 | 信息來源 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3831 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 80mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3832 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 60mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3833 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 40mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3834 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 30mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3835 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 20mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3836 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 15mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3837 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 10mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3838 | 鹽酸羥考酮緩釋片 | Oxycodone Hydrochloride Prolonged-release Tablets/OXYCONTIN | 5mg | 片劑 | NAPP PHARMACEUTICALS LIMITED | 原研進口 | 第十三批 | ||||||||||
| 3839 | 復方甘草酸苷片 | Compound Glycyrrhizin Tablets/Stronger Neo-Minophagen C(美能) | 甘草酸單銨鹽35mg（甘草酸苷25mg）、甘氨酸25mg、DL-蛋氨酸25mg | 片劑 | Minophagen Pharmaceutical Co., Ltd. | 原研進口 | 第十三批 | ||||||||||
| 3840 | 瑞格列奈二甲雙胍片 | Repaglinide and Metformin Hydrochloride Tablets/-- | 2mg/500mg | 片劑 | LUPIN LTD | 美國橙皮書 | 第十三批 | ||||||||||
? 2021 杭州百誠醫藥科技股份有限公司. ALL RIGHTS RESERVED
浙ICP備13034926號-1
(浙)-非經營性-2022-0016 浙公網安備 33010802005916號
? 2021 杭州百誠醫藥科技股份有限公司. ALL RIGHTS RESERVED浙ICP備13034926號-1 (浙)-非經營性-2022-0016 浙公網安備 33010802005916號
You are welcome to contact us via the online form below.
We will answer your inquiries in various ways, and jointly provide customized professional consultation and solutions for your research and development needs.
